# MT-228

Source: https://onco.cc/drugs/mt-228/  
OnCo record `mt-228` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MT-228 is an experimental small molecule from Myosin Therapeutics, in preclinical development for undisclosed cancer.

## Summary

MT-228 is a small molecule from Myosin Therapeutics. A small-molecule inhibitor of non-muscle myosin IIA and IIB (the products of MYH9 and MYH10) being pursued for non-orphan oncology indications. Its furthest stage is preclinical development, for undisclosed cancer. No clinical trial naming it is registered on ClinicalTrials.gov. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: MT-228
- Modality: Small molecule
- Mechanism: A small-molecule inhibitor of non-muscle myosin IIA and IIB (the products of MYH9 and MYH10) being pursued for non-orphan oncology indications.

## Sources

- Myosin Therapeutics: myosintherapeutics.com: https://www.myosintherapeutics.com/pipeline.php
- Myosin Therapeutics: myosintherapeutics.com: https://www.myosintherapeutics.com/pipeline.php

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [MYH9](https://onco.cc/targets/myh9/)
- companies: [Myosin Therapeutics](https://onco.cc/companies/myosin-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/mt-228.json